Marcus Lind

8.0k total citations · 3 hit papers
135 papers, 5.1k citations indexed

About

Marcus Lind is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Marcus Lind has authored 135 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Endocrinology, Diabetes and Metabolism, 37 papers in Surgery and 31 papers in Genetics. Recurrent topics in Marcus Lind's work include Diabetes Management and Research (96 papers), Diabetes Treatment and Management (78 papers) and Pancreatic function and diabetes (32 papers). Marcus Lind is often cited by papers focused on Diabetes Management and Research (96 papers), Diabetes Treatment and Management (78 papers) and Pancreatic function and diabetes (32 papers). Marcus Lind collaborates with scholars based in Sweden, United States and Germany. Marcus Lind's co-authors include Ann‐Marie Svensson, Annika Rosengren, Sofia Dahlqvist, Aldina Pivodic, Soffia Guðbjörnsdóttir, Hans Wedel, Mikhail Kosiborod, Mark A. Clements, Arndís F. Ólafsdóttir and Björn Eliasson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Marcus Lind

126 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Excess Mortality among Persons with Type 2 Diabetes

2015 721 citations Annika Rosengren, Aldina Pivodic et al. profile →
Glycemic Control and Excess Mortality in Type 1 Diabetes

2014 673 citations Marcus Lind, Aldina Pivodic et al. profile →
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections

2017 529 citations Marcus Lind, William H. Polonsky et al. JAMA profile →

Peers

Countries citing papers authored by Marcus Lind

Since Specialization

Citations

This map shows the geographic impact of Marcus Lind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Lind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Lind more than expected).

Fields of papers citing papers by Marcus Lind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus Lind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Lind. The network helps show where Marcus Lind may publish in the future.

Co-authorship network of co-authors of Marcus Lind

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Lind. A scholar is included among the top collaborators of Marcus Lind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Lind. Marcus Lind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating the Adequacy of Coefficient of Variation and Standard Deviation as Metrics of Glucose Variability in Type 1 Diabetes Based on Data from the GOLD and SILVER Trials 2025 ·Diabetes Technology & Therapeutics ·(unknown), Henrik Imberg, (unknown), Irl B. Hirsch, Johan Mårtensson, (unknown), Tim Heise, Marcus Lind	0
2	Accuracy of Glucose Trends by Subcutaneous Continuous Monitoring vs Intermittent Arterial Measurements in Critically Ill Patients 2025 ·Journal of Diabetes Science and Technology ·Ola Friman, Marcus Lind, Ragnar Thobaben, P Zetterqvist, Anders Perner, (unknown), Anders Oldner, Johan Mårtensson	0
3	Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial 2025 ·Cardiovascular Diabetology ·(unknown), (unknown), Bochra Zareini, Ulrik Pedersen‐Bjergaard, (unknown), (unknown), Mikkel Porsborg Andersen, Rasmus Bo Hasselbalch, Henrik Imberg, (unknown), Marcus Lind, (unknown), Pratik Choudhary, (unknown), (unknown), Stefanie Lanzinger, Julia K. Mader, Thomas Alexander Gerds, Christian Torp‐Pedersen	0
4	Prevention of glucocorticoid-induced impairment of bone metabolism—a randomized, placebo-controlled, single centre proof-of-concept clinical trial 2025 ·JBMR Plus ·(unknown), Lisa Johansson, (unknown), Henrik Imberg, Per Magnusson, Marcus Lind, Mattias Lorentzon	1
5	Trends in Survival After First Myocardial Infarction in People With Diabetes 2024 ·Journal of the American Heart Association ·L. E. Glynn, Marcus Lind, Tomas Andersson, Björn Eliasson, Robin Hofmann, Thomas Nyström	2
6	Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes 2024 ·Journal of Diabetes Science and Technology ·(unknown), Henrik Imberg, (unknown), (unknown), Johan Jendle, Bengt-Olov Tengmark, Anna Folino, (unknown), Marcus Lind	7
7	Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials 2024 ·Diabetologia ·(unknown), Henrik Imberg, Irl B. Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, (unknown), Arndís F. Ólafsdóttir, (unknown), William H. Polonsky, Marcus Lind	8
8	Performance of Subcutaneous Continuous Glucose Monitoring in Adult Critically Ill Patients Receiving Vasopressor Therapy 2024 ·Diabetes Technology & Therapeutics ·Ola Friman, (unknown), Marcus Lind, P Zetterqvist, (unknown), Anders Perner, Anders Oldner, Olav Rooyackers, Johan Mårtensson	8
9	Mortality in Patients With Primary Aldosteronism: A Swedish Nationwide Study 2023 ·Hypertension ·(unknown), Tatiana Zverkova Sandström, Annika Rosengren, Penelope Trimpou, Daniel S Olsson, Marcus Lind, Andreas Muth, Gudmundur Johannsson, Óskar Ragnarsson	9
10	The effect of carbohydrate intake on glycaemic control in individuals with type 1 diabetes: a randomised, open-label, crossover trial 2023 ·The Lancet Regional Health - Europe ·(unknown), Arndís F. Ólafsdóttir, (unknown), Henrik Imberg, Eva Toft, (unknown), Ulf Rosenqvist, (unknown), Marcus Lind	4
11	Glycaemic control and sepsis risk in adults with type 1 diabetes 2023 ·Diabetes Obesity and Metabolism ·(unknown), Marcus Lind, Mikael Andersson, Anders Oldner, Maria Cronhjort, Björn Eliasson, Christer Svensén, Johan Mårtensson	6
12	Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK 2023 ·BMJ Open Diabetes Research & Care ·Antonio González‐Pérez, David Vizcaya, María Eugenia Sáez, Marcus Lind, Luis A. Garcı́a Rodrı́guez	7
13	Evaluating a systematic intensive therapy using continuous glucose monitoring and intermittent scanning glucose monitoring in clinical diabetes care: a protocol for a multi-center randomized clinical trial 2023 ·SHILAP Revista de lepidopterología ·Arndís F. Ólafsdóttir, Marcus Lind	0
14	Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol 2022 ·BMJ Open ·Johnny Ludvigsson, (unknown), Christoph Nowak, Pedro Filipe Teixeira, (unknown), (unknown), Rosaura Casas, Marcus Lind, Ulf Hannelius	7
15	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88 2021 ·Diabetes Care ·Marcus Lind, Henrik Imberg, Ruth L. Coleman, Olle Nerman, Rury R. Holman	75
16	Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections 2021 ·Diabetes Technology & Therapeutics ·(unknown), Irl B. Hirsch, Magnus Ekelund, (unknown), (unknown), Sofia Dahlqvist, Johan Svensson, Marcus Lind	3
17	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5) 2018 ·Obesity Science & Practice ·(unknown), Karin Filipsson, (unknown), (unknown), Henrik Imberg, Stefan Sjöberg, Bo Åhrén, Sofia Dahlqvist, Thomas Gustafsson, Jaakko Tuomilehto, Irl B. Hirsch, Marcus Lind	12
18	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections breakdown → 2017 ·JAMA ·Marcus Lind, William H. Polonsky, Irl B. Hirsch, Tim Heise, Jan Bolinder, Sofia Dahlqvist, (unknown), Arndís F. Ólafsdóttir, Anders Frid, Hans Wedel, (unknown), Thomas Nyström, Jarl Hellman	529
19	A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes 2014 ·Diabetes Technology & Therapeutics ·(unknown), Jeffrey I. Joseph, (unknown), Irl B. Hirsch, Stig Attvall, Aldina Pivodic, Sofia Dahlqvist, David C. Klonoff, Börje Haraldsson, Marcus Lind	70
20	The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables 2009 ·PLoS ONE ·Marcus Lind, Anders Odén, Martin Fahlén, Björn Eliasson	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact